10-Day structured initiation protocol from multiple daily injection to hybrid closed-loop system in children and adolescents with type 1 diabetes
Goran Petrovski, Fawziya Al Khalaf, Judith Campbell, Hannah Fisher, Fareeda Umer, Khalid Hussain, Goran Petrovski, Fawziya Al Khalaf, Judith Campbell, Hannah Fisher, Fareeda Umer, Khalid Hussain
Abstract
Aim: The aim of this study was to evaluate the 10-day initiation protocol for MiniMed 670G hybrid closed-loop (HCL) system in individuals with type 1 diabetes on multiple daily injection (MDI) in achieving desirable glycemic control.
Methods: An open-label single-arm, single-center, clinical investigation in children aged 7-18 years on MDI following a structured protocol: 2 days, HCL system assessment; 5 days, HCL system training (2-h sessions on 5 consecutive days with groups of 3-5 participants and families); 3 days, Manual Mode use of HCL system; 84 days, Auto Mode use of the HCL system, cumulating in 10 days from MDI to Auto Mode activation.
Results: A total of 30 children (age 10.24 ± 2.6 years) were enrolled in the study, and all completed the planned 84 days on Auto Mode. The participants used the sensor for a median of 92% of the time and spent a median of 89% in Auto Mode. The mean HbA1c decreased from 8.2 ± 1.4% (66 ± 15.3 mmol/mol) at baseline to 6.7 ± 0.5% (50 ± 5.5 mmol/mol) at the end of the study (p = 0.017). Time in range (70-180 mg/dL) increased from 46.9 ± 18.5% at baseline to 75.6 ± 6.9% in Auto Mode (p < 0.001). This was achieved while spending 2.8% of the time below 70 mg/dL and without any severe hypoglycemia or DKA.
Conclusion: Children and adolescents with type 1 diabetes on MDI therapy can successfully initiate the HCL system, using a concise structured 10-day protocol.
Keywords: Hybrid closed-loop system; Multiple daily injection; Protocol; Type 1 diabetes.
Conflict of interest statement
The authors declare that they have no conflict of interest.
Figures
References
- American Diabetes Association Glycemic targets: standards of medical care in diabetes-2019. Diabetes Care. 2019;42(11):S61–S70. doi: 10.2337/dc19-S006.
- DiMeglio LA, Acerini CL, Codner E, et al. ISPAD clinical practice consensus guidelines 2018: glycemic control targets and glucose monitoring for children, adolescents, and young adults with diabetes. Pediatr Diabetes. 2018;19(S27):105–114. doi: 10.1111/pedi.12737.
- Ly TT, Nicholas JA, Retterath A, et al. Effect of sensor-augmented insulin pump therapy and automated insulin suspension vs standard insulin pump therapy on hypoglycaemia in patients with type 1 diabetes. A randomized clinical trial. JAMA. 2013;310(12):1240–1247. doi: 10.1001/jama.2013.277818.
- Bergenstal RM, Klonoff DC, Garg SK, for the ASPIRE In-Home Study Group et al. Threshold-based insulin pump interruption for reduction of hypoglycemia. N Engl J Med. 2013;369:224–232. doi: 10.1056/NEJMoa1303576.
- Bosi E, Choudhary P, de Valk HW, et al. Efficacy and safety of suspend-before-low insulin pump technology in hypoglycaemia-prone adults with type 1 diabetes (SMILE): an open-label randomised controlled trial. Lancet Diabetes Endocrinol. 2019;7(6):462–472. doi: 10.1016/S2213-8587(19)30150-0.
- Battelino T, Nimri R, Dovc K, Phillip M, Bratina N. Prevention of hypoglycemia with predictive low glucose insulin suspension in children with type 1 diabetes: a randomized controlled trial. Diabetes Care. 2017;40:764–770. doi: 10.2337/dc16-2584.
- Thabit H, Hovorka R. Coming of age: the artificial pancreas for type 1 diabetes. Diabetologia. 2016;59:1795–1805. doi: 10.1007/s00125-016-4022-4.
- Kropff J, DeVries JH. Continuous glucose monitoring, future products, and update on worldwide artificial pancreas projects. Diabetes Technol Ther. 2016;18(S2):S253–S263. doi: 10.1089/dia.2015.0345.
- Shah VN, Shoskes A, Tawfik B, Garg SK. Closed loop system in the management of diabetes: past, present, and future. Diabetes Technol Ther. 2014;16:477–490. doi: 10.1089/dia.2014.0193.
- Biester T, Nir J, Remus K, et al. DREAM5: an open-label, randomized, cross-over study to evaluate the safety and efficacy of day and night closed-loop control by comparing the MD-Logic automated insulin delivery system to sensor augmented pump therapy in patients with type 1 diabetes at home. Diabetes Obes Metab. 2018;26:1–7.
- Nimri R, Bratina N, Kordonouri O, et al. MD-Logic overnight type 1 diabetes control in home settings: multicenter, multinational, single blind, randomized trial. Diabetes Obes Metab. 2017;19:553–561. doi: 10.1111/dom.12852.
- U.S. Food and Drug Administration (2019) FDA approves first automated insulin delivery device for type 1 diabetes. . Accessed 21 Mar 2019
- U.S. Food and Drug Administration (2019) FDA approves automated insulin delivery and monitoring system for use in younger pediatric patients. . Accessed 21 July 2019
- U.S. Food and Drug Administration (2019) FDA summary of safety and effectiveness data; PMA P160017. . Accessed 18 Apr 2019
- Weaver KW, Hirsch IB. The hybrid closed-loop system: evolution and practical applications. Diabetes Technol Ther. 2018;20(S2):S216–S223. doi: 10.1089/dia.2018.0091.
- Trevitt S, Simpson S, Wood A. Artificial pancreas device systems for the closed-loop control of type 1 diabetes: what systems are in development. J Diabetes Sci Technol. 2016;10:714–723. doi: 10.1177/1932296815617968.
- Forlenza GP, Pinhas-Hamiel O, Liljenquist DR, et al. Safety evaluation of the MiniMed 670G system in children 7–13 years of age with type 1 diabetes. Diabetes Technol Ther. 2019;21(1):11–19. doi: 10.1089/dia.2018.0264.
- Bergenstal RM, Garg S, Weinzimer SA, et al. Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes. JAMA. 2016;316:1407–1408. doi: 10.1001/jama.2016.11708.
- Garg SK, Weinzimer SA, Tamborlane WV, et al. Glucose outcomes with the in-home use of a hybrid closed-loop insulin delivery system in adolescents and adults with type 1 diabetes. Diabetes Technol Ther. 2017;19:155–163. doi: 10.1089/dia.2016.0421.
- Aleppo G, Webb KM. Integrated insulin pump and continuous glucose monitoring technology in diabetes care today: a perspective of real-life experience with the MiniMed™ 670G hybrid closed-loop system. Endocr Pract. 2018;24(7):684–692. doi: 10.4158/EP-2018-0097.
- Petrovski G, Al Khalaf F, Hussain K, et al. Continuous subcutaneous insulin infusion characteristics in type 1 diabetes children and adolescents in Qatar. Diabetes Ther. 2018;9(5):2091–2098. doi: 10.1007/s13300-018-0510-5.
- Petrovski G, Zivkovic M, Stratrova SS, et al. Type 1 diabetes and long-term continuous subcutaneous insulin infusion therapy: a 10-year experience from Macedonia. Diabetes Technol Ther. 2017;19(12):739–743. doi: 10.1089/dia.2017.0227.
- Rodbard D. Continuous glucose monitoring: a review of recent studies demonstrating improved glycemic outcomes. Diabetes Technol Ther. 2017;19(S3):S25–S37. doi: 10.1089/dia.2017.0035.
- Wright LA, Hirsch IB. Metrics beyond hemoglobin A1C in diabetes management: time in range, hypoglycemia, and other parameters. Diabetes Technol Ther. 2017;19(S2):S16–S26. doi: 10.1089/dia.2017.0029.
- Battelino T, Danne T, Bergenstal R, et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care. 2019 doi: 10.2337/dci19-0028.
- Messer LH, Forlenza GP, Sherr JL, et al. Optimizing hybrid closed-loop therapy in adolescents and emerging adults using the MiniMed 670G system. Diabetes Care. 2018;41(4):789–796. doi: 10.2337/dc17-1682.
- Messer LH, Forlenza GP, Wadwa RP, et al. The dawn of automated insulin delivery: a new clinical framework to conceptualize insulin administration. Pediatr Diabetes. 2018;19:14–17. doi: 10.1111/pedi.12535.
- Tauschmann M, Allen JM, Wilinska ME, et al. Day-and-night hybrid closed-loop insulin delivery in adolescents with type 1 diabetes: a free-living, randomized clinical trial. Diabetes Care. 2016;39:1168–1174. doi: 10.2337/dc15-2078.
- Doyle FJ, 3rd, Huyett LM, Lee JB, et al. Closed-loop artificial pancreas systems: engineering the algorithms. Diabetes Care. 2014;37:1191–1197. doi: 10.2337/dc13-2108.
- Dassau E, Pinsker JE, Kudva YC, et al. Twelve-week 24/7 ambulatory artificial pancreas with weekly adaptation of insulin delivery settings: effect on hemoglobin A1c and hypoglycemia. Diabetes Care. 2017;40:1719–1726. doi: 10.2337/dc17-1188.
- Cordero TL, Garg SK, Brazg RL, et al. The effect of prior continuous glucose monitoring use on glycemic outcomes in the pivotal trial of the MiniMed™ 670G hybrid closed-loop system. Diabetes Technol Ther. 2017;16:338–347.
Source: PubMed